Arbutus Biopharma (ABUS) vs Pharming Group N.V. (PHAR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Arbutus Biopharma (ABUS) has outperformed Pharming Group N.V. (PHAR) over the past year, gaining 0.0% versus a loss of 34.2%. Over five years, ABUS leads with a +5.1% price change compared with +2.2% for PHAR. Pharming Group N.V. is the larger company by market cap ($683.0 million vs $657.6 million), about 1.0 times the size.
On valuation, Arbutus Biopharma trades at a lower trailing P/E (5.4x vs 74.2x for Pharming Group N.V.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | PHAR |
|---|---|---|
| Share price | $4.29 | $9.65 |
| Market cap | $657.55M | $683.01M |
| 1-day change | -4.24% | -0.31% |
| YTD return | -10.81% | -45.39% |
| 1-year return | 0.00% | -34.22% |
| 5-year return | +5.15% | +2.22% |
| P/E ratio (TTM) | 5.43 | 74.23 |
| Forward P/E | — | 31.43 |
| EPS (TTM) | $0.79 | $0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $21.34 |
| 52-week low | $3.50 | $9.59 |
| Distance from 52-week high | -21.28% | -54.78% |
| Average volume | 4.65M | 22.88K |
| Shares outstanding | 153.28M | 70.78M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABUS has outperformed PHAR by 34.2 percentage points over the past year.
- Pharming Group N.V. trades at a higher earnings multiple (74.2x vs 5.4x trailing P/E).
ABUS vs PHAR FAQ
Which is bigger, Arbutus Biopharma or Pharming Group N.V.?
Pharming Group N.V. (PHAR) is larger, with a market capitalization of $683.01M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or PHAR?
ABUS returned 0.00% over the past 12 months, compared with -34.22% for PHAR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABUS or PHAR?
ABUS has the lower trailing P/E at 5.4, versus 74.2 for PHAR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and Pharming Group N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.